APRE Stock Summary and Trading Ideas (Aprea Therapeutics | NASDAQ:APRE)

Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.

Aprea Therapeutics trades on the NASDAQ stock market under the symbol APRE.

As of January 13, 2026, APRE stock price declined to $0.91 with 86,397 million shares trading.

APRE has a beta of 2.24, meaning it tends to be more sensitive to market movements. APRE has a correlation of 0.34 to the broad based SPY ETF.

APRE has a market cap of $6.36 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, APRE traded as high as $12.00 and as low as $.47.

The top ETF exchange traded funds that APRE belongs to (by Net Assets): VXF.

APRE has underperformed the market in the last year with a price return of -75.1% while the SPY ETF gained +20.6%. APRE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -35.9% and -1.1%, respectively, while the SPY returned +6.4% and +0.7%, respectively.

APRE support price is $.88 and resistance is $.96 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that APRE shares will trade within this expected range on the day.